ATE404208T1 - Uridin-therapie für patienten mit erhöhten purin- werten - Google Patents

Uridin-therapie für patienten mit erhöhten purin- werten

Info

Publication number
ATE404208T1
ATE404208T1 AT01979786T AT01979786T ATE404208T1 AT E404208 T1 ATE404208 T1 AT E404208T1 AT 01979786 T AT01979786 T AT 01979786T AT 01979786 T AT01979786 T AT 01979786T AT E404208 T1 ATE404208 T1 AT E404208T1
Authority
AT
Austria
Prior art keywords
patients
purine levels
uridine
elevated purine
elevated
Prior art date
Application number
AT01979786T
Other languages
English (en)
Inventor
Theodore Page
Deborah Brewer
Charles Moseley
Original Assignee
Repligen Corp
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24768963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE404208(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repligen Corp, Univ California filed Critical Repligen Corp
Application granted granted Critical
Publication of ATE404208T1 publication Critical patent/ATE404208T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01979786T 2000-10-12 2001-10-12 Uridin-therapie für patienten mit erhöhten purin- werten ATE404208T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/689,551 US6727231B1 (en) 2000-10-12 2000-10-12 Uridine therapy for patients with elevated purine levels

Publications (1)

Publication Number Publication Date
ATE404208T1 true ATE404208T1 (de) 2008-08-15

Family

ID=24768963

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01979786T ATE404208T1 (de) 2000-10-12 2001-10-12 Uridin-therapie für patienten mit erhöhten purin- werten

Country Status (8)

Country Link
US (1) US6727231B1 (de)
EP (1) EP1324761B1 (de)
JP (1) JP2004527460A (de)
AT (1) ATE404208T1 (de)
AU (2) AU1171102A (de)
CA (1) CA2425593A1 (de)
DE (1) DE60135358D1 (de)
WO (1) WO2002030354A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US7440590B1 (en) * 2002-05-21 2008-10-21 University Of Kentucky Research Foundation System and technique for retrieving depth information about a surface by projecting a composite image of modulated light patterns
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005123097A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
EP1813623B1 (de) * 2004-09-17 2011-11-09 Kissei Pharmaceutical Co., Ltd. In der 8-stellung modifiziertes purin-nukleosidderivat und dessen medizinische verwendung
AU2005286672B2 (en) * 2004-09-23 2009-03-12 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
JP4778946B2 (ja) * 2007-12-03 2011-09-21 明治飼糧株式会社 血中尿酸値低下剤
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
EP4012414A1 (de) * 2020-12-11 2022-06-15 Stalicla S.A. Diagnose von autismus-spektrum-störung phänotyp 1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
IL108524A0 (en) 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
PT1140104E (pt) * 1998-07-31 2007-12-26 Massachusetts Inst Technology Tratamento da doença de alzheimer, in vivo, por aumento dos níveis de citidina
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
RU2394580C2 (ru) * 1999-02-23 2010-07-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы лечения митохондриальных нарушений

Also Published As

Publication number Publication date
US6727231B1 (en) 2004-04-27
JP2004527460A (ja) 2004-09-09
WO2002030354A3 (en) 2002-07-11
CA2425593A1 (en) 2002-04-18
EP1324761B1 (de) 2008-08-13
DE60135358D1 (de) 2008-09-25
AU2002211711B2 (en) 2007-05-17
EP1324761A2 (de) 2003-07-09
EP1324761A4 (de) 2004-09-08
WO2002030354A2 (en) 2002-04-18
AU1171102A (en) 2002-04-22

Similar Documents

Publication Publication Date Title
ATE404208T1 (de) Uridin-therapie für patienten mit erhöhten purin- werten
IL273422A (en) Methods and systems for extracorporeal organ treatment
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
AU2002366641A1 (en) Methods for inhibiting ocular processes
DE60037578D1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
BR0211986A (pt) 29-enóis de rapamicina
MY139142A (en) Short corridor progressive addition lenses with reduced unwanted astigmatism
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
BR9913517A (pt) Composição, dispositivo, e, uso de uma composição
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
DE69737592D1 (de) Mittel gegen juckreiz
DE69910045D1 (de) Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
BG105112A (bg) Средство с антидепресивно действие
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
EP1558766A4 (de) Verwendung von a33-antigenen und jam-it
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
PT1143917E (pt) Derivados anticonvulsionantes uteis no tratamento da perturbacao de stress pos-traumatico
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
ATE418613T1 (de) Antimikrobielle zusammensetzungen
PE20399A1 (es) Muteina ob
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties